GenScript Biotech Corporation's ESG Rating Upgraded to AA by MSCI
Reuters
Aug 01
GenScript Biotech Corporation's ESG Rating Upgraded to AA by MSCI
GenScript Biotech Corporation has announced an upgrade in its ESG rating from A to AA by MSCI. This improvement reflects the company's performance in product safety, quality, and human capital development, along with advancements in environmental and governance practices. GenScript is recognized as an ESG leader globally, with the AA rating highlighting its commitment to sustainability in the biotech sector. The company is a participant of the United Nations Global Compact and a partner in the Pharmaceutical Supply Chain Initiative, focusing on human rights, labor, environmental issues, and anti-corruption. Additionally, GenScript has received a Silver Medal from EcoVadis and a "Low Risk" ESG rating from Morningstar Sustainalytics, and its carbon reduction targets have been validated by the Science Based Targets initiative.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Biotech Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42393) on August 01, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.